Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × INDUSTRY × Solid Cancer × Clear all

Phase

Status

Recruiting 3 Terminated 1 Completed 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 403 Carcinoma, Non-Small-Cell Lung 368 Breast Neoplasms 285 Neoplasm Metastasis 194 Colorectal Neoplasms 174 Melanoma 169 Leukemia, Myeloid, Acute 163 Multiple Myeloma 145 Recurrence 138 Prostatic Neoplasms 136 Ovarian Neoplasms 136 Lymphoma, Non-Hodgkin 125 Lung Neoplasms 107 Lymphoma 102 Pancreatic Neoplasms 100 Leukemia, Lymphocytic, Chronic, B-Cell 93 Squamous Cell Carcinoma of Head and Neck 89 Carcinoma, Renal Cell 88 Leukemia 75 Lymphoma, Large B-Cell, Diffuse 74 Carcinoma, Hepatocellular 73 Stomach Neoplasms 72 Lymphoma, Follicular 69 Head and Neck Neoplasms 66 Triple Negative Breast Neoplasms 64 Urinary Bladder Neoplasms 60 Myelodysplastic Syndromes 58 Glioblastoma 57 Small Cell Lung Carcinoma 50 Precursor Cell Lymphoblastic Leukemia-Lymphoma 43

Interventions

pembrolizumab 1 durvalumab 1 atezolizumab 1 S-Adenosylmethionine 1 Nivolumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03721679 2021-02-01

Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1

Oncovir, Inc.

Phase 1/2 Terminated

Solid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡